Boehringer's Weight Loss Candidate Trails Rivals in Diabetes and Obesity
The Phase III trial met its co-primary endpoints, with up to 13.1% weight loss and a 1.21% drop in HbA1c after 76 weeks, researchers said.
6 Articles
6 Articles
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1 Detailed results from the Phase III trial […]
The Record
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population…
Boehringer's weight loss candidate trails rivals in diabetes and obesity
MILAN — Boehringer Ingelheim’s lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes, according to data presented Thursday. The result trailed other ...
Coverage Details
Bias Distribution
- 75% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
